Shares of Bio-Techne Corporation (NASDAQ: TECH) surged 5.83% in pre-market trading on Wednesday, following the company's impressive second-quarter fiscal 2025 earnings report. The life sciences company reported better-than-expected financial results, fueling investor optimism and driving the stock higher.

Bio-Techne reported adjusted earnings per share (EPS) of $0.42 for the quarter ended December 31, 2024, surpassing the analyst consensus estimate of $0.39 by 7.69%. Additionally, the company's quarterly sales of $297.03 million exceeded the analyst consensus estimate of $285.98 million by 3.87%, representing an 8.96% year-over-year increase.

The strong financial performance can be attributed to Bio-Techne's continued growth in its core life sciences business, driven by robust demand for its innovative tools and bioactive reagents used in research and clinical diagnostic applications. The company's ability to consistently deliver solid earnings and revenue growth has reinforced investor confidence, leading to the pre-market surge in its stock price.